UNH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
UnitedHealth Group Inc (UNH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has potential for recovery, its recent financial performance, technical indicators, and analyst sentiment suggest caution. The stock's pre-market price is declining, and there are no strong proprietary trading signals to indicate a compelling entry point. Holding off for now may be a better approach.
The technical indicators for UNH are bearish. The MACD is negatively expanding, the RSI is neutral at 26.55, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 269.542) but shows no clear signs of reversal. The pre-market price is also down by 0.39%, indicating weak momentum.
UnitedHealth is implementing measures to address rising healthcare costs and improve performance. Analysts note potential for recovery in the long term, and the company has recommitted to its long-term adjusted EPS growth target of 13%-16%.
The company's Q4 2025 financial results showed a significant decline in net income (-99.82% YoY) and EPS (-99.83% YoY). Analysts have lowered price targets significantly, citing disappointing Medicare Advantage rates and uncertainty around future earnings. Technical indicators and trading sentiment are weak, with no significant hedge fund or insider activity.
In Q4 2025, revenue increased by 13.46% YoY to $113.575 billion, but net income dropped drastically to $10 million (-99.82% YoY), and EPS fell to $0.01 (-99.83% YoY). The gross margin remained flat at 0%. This indicates significant profitability challenges despite revenue growth.
Analyst sentiment is mixed but leaning negative. Multiple firms have lowered price targets, with the average target now in the $350-$410 range. Analysts maintain Overweight or Buy ratings but express concerns about Medicare Advantage rates, earnings visibility, and restructuring at Optum.
